Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - JUNIPER PHARMACEUTICALS INC | d275921dex322.htm |
| EX-21 - EX-21 - JUNIPER PHARMACEUTICALS INC | d275921dex21.htm |
| EX-31.2 - EX-31.2 - JUNIPER PHARMACEUTICALS INC | d275921dex312.htm |
| EX-32.1 - EX-32.1 - JUNIPER PHARMACEUTICALS INC | d275921dex321.htm |
| EX-31.1 - EX-31.1 - JUNIPER PHARMACEUTICALS INC | d275921dex311.htm |
| 10-K - FORM 10-K - JUNIPER PHARMACEUTICALS INC | d275921d10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Juniper Pharmaceuticals, Inc.
Boston, Massachusetts
We hereby consent to the incorporation by reference in the Registration Statement on Forms S-3 (Nos. 333-206928, 333-169599, 333-75275, 333-125671, 333-132803, 333-140107, and 333-37976) and Forms S-8 (Nos. 333-152008, 333-188647 and 333-205723) of Juniper Pharmaceuticals, Inc. (formerly Columbia Laboratories, Inc.) of our report dated March 10, 2016, relating to the consolidated financial statements which appears in this Annual Report on Form 10-K.
/s/ BDO USA, LLP
Boston, Massachusetts
March 10, 2016